Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type 2 Diabetes
Phase PHASE4
Enrollment 34
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

SGLT2 inhibitors have demonstrated to mitigate cardiorenal risk in people with type 2 diabetes and are likely to play an increasingly large role in the treatment of patients with diabetes, chronic kidney disease and hypertension. Yet the underlying mechanisms of its protective effects are incompletely understood and the salutary effect may be altered by dietary factors such as sodium intake. Therefore, carefully designed mechanistic trials are needed to better understand the interplay between ertugliflozin and salt intake and to potentially modify salt intake to maximize treatment response. In addition, the study could contribute to hypotheses concerning the effects of SGLT2 inhibitors in combination with other drugs that affect sodium homeostasis and could help to explain the differences in kidney outcomes observed in (outcome) trials, which include different ethnicities with potential differences in dietary habits.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: ertugliflozine — SGLT2i versus placebo
  • Behavioral: low salt diet — comparing low salt versus high salt diet
  • Drug: placebo — placebo tablet
  • Behavioral: high salt diet — high salt diet

Primary Outcomes

  • Blood pressure (7 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-07-25
Completion: 2025-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 34 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Amsterdam UMC, location VUmc
Collaborators: Children's Hospital Colorado
Contact Information
Study Contact:
Jessica Kendrick, Prof.
303-724-4837
Jessica.Kendrick@cuanschutz.edu
Childrens hospital colorado
Daniel H van Raalte, Prof. Dr.
+31-20-4440534
d.vanraalte@amsterdamumc.nl
Amsterdam UMC
Interventions
  • Drug: ertugliflozine — SGLT2i versus placebo
  • Behavioral: low salt diet — comparing low salt versus high salt diet
  • Drug: placebo — placebo tablet
  • Behavioral: high salt diet — high salt diet
Study Locations (2 sites)
Childrens hospital colorado, Denver, Colorado 80045 United States
Amsterdam UMC, Amsterdam, Netherlands
Eligibility Criteria
Inclusion Criteria: Adults with previously diagnosed T2DM according to American Diabetes Association (ADA) criteria * HbA1c 6.5-10% * Age 18 - 85 years of age * Overweight or obese with BMI: \>25 kg/m2 * We will make every effort to enrol participants of all races/ethnicities." * Both sexes (females must be post-menopausal; no menses \>1 year; in case of doubt, Follicle-Stimulating Hormone (FSH) will be determined with cut-off defined as \>31 U/L) * Ability to provide signed and dated, written informed consent prior to any study procedures * Estimated GFR 60-90 ml/min/1.73m2 by CKD-EPI matching the eGFR range of most participants in VERTIS-CV * Sodium intake at baseline \< 200 mmol/day * UACR \< 30 mg/mmol * All participants need to be on a stable dose of diabetes medication, including Metformin, SU, DPP4-inhibitors, or insulin. * Participants suffering from hypertension need to be on a stable dose of RAS inhibitors. In case RAS inhibition is not tolerated, the participant should to be on a stable dose of other antihypertensive treatment. Exclusion Criteria: * History of unstable or rapidly progressing renal disease NL80772.029.22 / DC2022ERTU DESIGN Protocol DESIGN, Study NO. 2022.0737 Version 5.0dd22-02-2024 14 of 45 * Estimated GFR \<60 mL/min/1.73m2 or eGFR \> 90 mL/min/1.73m2 determined by CKD-EPI * UACR \> 30 mg/mmol * Current/chronic use of the following medication: SGLT2 inhibitors, TZD, GLP-1RA, glucocorticoids, immune suppressants, antimicrobial agents, chemotherapeutics Participants should be on a stable dose of antipsychotics, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Subjects on diuretics will only be excluded when these drugs cannot be stopped for the duration of the study. * Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) will not be allowed, unless used as incidental medication (1-2 tablets) for non-chronic indications (i.e. sports injury, headache or back ache). However, no such drug can be taken within a timeframe of 2 weeks prior to renal testing * History of diabetic ketoacidosis (DKA) requiring medical intervention (e.g. emergency room visit and/or hospitalization) within 1 month prior to the Screening visit. * Current urinary tract infection and active nephritis * Recent (\<6 months) history of cardiovascular disease, including: * Acute coronary syndrome * Chronic heart failure (New York Heart Association grade II-IV) * Stroke or transient ischemic neurologic disorder * Severe hepatic insufficiency and/or significant abnormal liver function defined as aspartate aminotransferase (AST) \>3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) \>3x ULN * Active malignancy. History of malignancy is allowed unless the participant still has active treatment other than hormonal therapy.• History of or actual severe mental disease * Substance abuse (alcohol: defined as \>4 units/day) * Allergy to any of the agents used in the study * Individuals who are investigator site personnel, directly affiliated with the study, or are immediate (spouse, parent, child, or sibling, whether biological or legally adopted) family of investigator site personnel directly affiliated with the study * Inability to understand the study protocol or give informed consent
Conditions Diabetes Mellitus, Coronary Artery Bypas...
Phase NA
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized, double-blind, prospective clinical trial aims to investigate the effect of remote ischemic preconditioning (RIPC) on myocardial protection in patients with type 2 diabetes mellitus undergoing elective coronary artery bypass graft (CABG) surgery. Perioperative myocardial injury remains a significant concern during CABG, particularly in high-risk patients such as those with diabetes. RIPC is a low-cost, non-invasive intervention that may reduce myocardial damage by enhancing ischemic tolerance through intermittent limb ischemia. Sixty patients aged 40-85 years with type 2 diabetes scheduled for isolated CABG will be randomized to either receive RIPC or standard care. RIPC will be applied through five cycles of upper limb cuff inflation and deflation prior to sternotomy. High-sensitivity troponin T levels will be measured at 24, 48, and 72 hours postoperatively to assess myocardial injury. Secondary outcomes include acute kidney injury (KDIGO classification), maximum vasoactive-inotropic score (VIS) during the first 72 postoperative hours, ICU and hospital length of stay. This study will provide insight into the cardioprotective role of RIPC in diabetic patients undergoing cardiac surgery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Procedure: Remote Ischemic Preconditioning — Remote ischemic preconditioning (RIPC) will be performed after anesthesia induction and before surgical incision. A standard blood pressure cuff will be placed on the upper limb (without arterial cannulation), inflated to 200 mmHg for 5 minutes, and then deflated for 5 minutes. This cycle will be repeated five times prior to sternotomy. The procedure will be carried out under general anesthesia, ensuring patient blinding. No pharmacological agents are involved in this intervention

Primary Outcomes

  • Postoperative 24-hour high-sensitivity Troponin T level (24 hours after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-26
Completion: 2025-09-15
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Muğla Sıtkı Koçman University
Contact Information
Study Contact:
Melike Korkmaz Toker, Associate Professor
00905054747098
meltoker@gmail.com
Melike Korkmaz Toker
00905054747098
meltoker@gmail.com
Mugla Training and Research Hospital
Melike Korkmaz Toker
meltoker@gmail.com
Mugla Training and Research Hospital
Interventions
  • Procedure: Remote Ischemic Preconditioning — Remote ischemic preconditioning (RIPC) will be performed after anesthesia induction and before surgical incision. A standard blood pressure cuff will be placed on the upper limb (without arterial cannulation), inflated to 200 mmHg for 5 minutes, and then deflated for 5 minutes. This cycle will be repeated five times prior to sternotomy. The procedure will be carried out under general anesthesia, ensuring patient blinding. No pharmacological agents are involved in this intervention
Study Locations (2 sites)
Mugla Training and Research Hospital, Muğla, 48000 Turkey (Türkiye)
Mugla Training and Research Hospital, Muğla, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Diagnosed with type 2 diabetes mellitus and receiving medical treatment * Scheduled for isolated elective coronary artery bypass graft (CABG) surgery * American Society of Anesthesiologists (ASA) physical status class III or IV * Age between 40 and 85 years Exclusion Criteria: Emergency CABG surgery Reoperation (revision surgery) Left ventricular ejection fraction (LVEF) \< 40% History of cardiac arrest or cardiogenic shock Pregnancy Clinically significant peripheral arterial disease affecting the upper limbs Hepatic dysfunction (bilirubin \> 20 μmol/L or INR \> 2.0) Renal failure (eGFR \< 20 mL/min/1.73 m²) Ongoing treatment with glibenclamide or nicorandil (agents known to interfere with ischemic preconditioning mechanisms) Asthma
Conditions Breast Cancer Invasive
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In this project, the investigators will develop novel optical coherence tomography (OCT)-Raman spectroscopy and autofluorescence (AF)-Raman spectroscopy systems based on a selective sampling approach optimised for high-resolution analysis of whole lumpectomy specimens and sentinel lymph node (SLN) biopsies, respectively. The aim of using optical coherence tomography is not to detect cancer directly, but rather to identify adipose tissue so that large adipose regions can be excluded from subsequent Raman spectroscopy measurements. Although OCT has limited ability to distinguish tumour tissue from the surrounding normal stroma, adipose tissue exhibits a distinctive appearance in optical coherence tomography images because of its low backscattering properties, resulting from adipocytes that are filled with lipids and contain small, flattened nuclei. In contrast, benign dense tissue (stroma, ducts, and lobules) and malignant tissue produce much stronger backscattering signals. These characteristic patterns enable adipose tissue to be distinguished from other breast tissues using classification models based on optical coherence tomography reflectivity profiles, achieving 94% sensitivity and 93% specificity. Excluding adipose tissue from further analysis reduces the number of Raman spectroscopy measurements required, allowing the remaining, smaller tissue regions to be examined to discriminate between benign and malignant tissue. This flexible and adaptable scanning strategy is expected to improve both diagnostic accuracy and scanning speed, enabling complete assessment of surgical margins within clinically practical timescales. In addition, the investigators will develop a novel (AF)-Raman spectroscopy system based on a selective sampling approach optimised for high-resolution analysis of sentinel lymph node specimens. The purpose of incorporating autofluorescence imaging is to identify the optimal sampling locations for subsequent Raman spectroscopy measurements, thereby improving the efficiency of tissue interrogation while maintaining diagnostic accuracy.

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: OCT-Raman — a machine to detect positive margins in lumpectomy specimens
  • Diagnostic Test: AF-Raman — a machine for detection sentinel lymph nodes in Breast conserving surgery.

Primary Outcomes

  • Design and build unique OCT and AF-Raman system with integrated machine learning algorithms. (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-10-01
Completion: 2027-04-01
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Nottingham
Principal Investigators:
  • Ioan Notingher (PRINCIPAL_INVESTIGATOR) - University of Nottingham
  • Andrew Green (PRINCIPAL_INVESTIGATOR) - University of Nottingham
Contact Information
Study Contact:
Ioan Notingher
0)115 951 3082
ppzin@exmail.nottingham.ac.uk
Nehal Atallah
07521100084
msznma@nottingham.ac.uk
Nehal F Y Atallah, PhD
07521100084
msznma@nottingham.ac.uk
Nottingham university hospitals
Interventions
  • Diagnostic Test: OCT-Raman — a machine to detect positive margins in lumpectomy specimens
  • Diagnostic Test: AF-Raman — a machine for detection sentinel lymph nodes in Breast conserving surgery.
Study Locations (1 sites)
Nottingham university hospitals, Nottingham, United Kingdom
Eligibility Criteria
Inclusion criteria * Patients undergoing breast surgery wide local excision (WLE). * Able to give informed consent. * Any age. Exclusion criteria • Patients where there is any doubt regarding the diagnosis from pathologist as ascertained by previous diagnostic biopsy.
Conditions Depressive Disorder, Major
Phase PHASE3
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Fluoxetine — Fluoxetine is an antidepressant and belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs)
  • Drug: Roflumilast — Roflumilast is the first drug targeting PDE4 that was marketed for treatment of chronic obstructive pulmonary disease (COPD) with relatively weak potency inducing nausea and vomiting
  • Drug: Placebo — Placebo

Primary Outcomes

  • The principal measure of the outcome will be the 17-item Ham-D (2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-03-01
Completion: 2027-08-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tanta University
Contact Information
Study Contact:
Mostafa M I Bahaa, PhD
0201025538337
mbahaa@horus.edu.eg
Tanta Unuversity
Mostafa M Bahaa, PhD
Tanta Unuversity
Interventions
  • Drug: Fluoxetine — Fluoxetine is an antidepressant and belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs)
  • Drug: Roflumilast — Roflumilast is the first drug targeting PDE4 that was marketed for treatment of chronic obstructive pulmonary disease (COPD) with relatively weak potency inducing nausea and vomiting
  • Drug: Placebo — Placebo
Study Locations (1 sites)
Tanta Unuversity, Tanta, 31527 Egypt
Eligibility Criteria
Inclusion Criteria: 1. Patients with age greater than 18 years old. 2. Patients with Ham-D score at least 18 with item 1 depressed mood scored 2 or greater are eligible. Exclusion Criteria: 1. Patients with bipolar I or bipolar II disorder; eating disorders, personality disorders, and mental retardation, current diagnosis anxiety disorders (except for specific phobia), mental disorder due to general medical condition; met criteria for substance dependence or abuse in the previous three months; have a concurrent medical illness or history of seizures that would contraindicate use of the study medication and are receiving Electroconvulsive therapy (ECT). 2. Pregnant women or women not using medically accepted means of birth control are excluded. 3. Persons who score greater than 2 on the suicide item of the Ham-D, or who are judged to have significant suicidal ideation or potential in the view of an investigator, are excluded. 4. Patients who are required to be free of all psychotropic except for escitalopram and anti-inflammatory medications for at least four weeks before study entry.
Conditions HER2-positive Breast Cancer, Diarrhea Ca...
Phase NA
Enrollment 308
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the efficacy and safety of probiotics for the prevention of diarrhea in patients with breast cancer receiving the tyrosine kinase inhibitor (TKI) Neratinib. Study Design: This is a prospective, randomized controlled clinical trial. Participants will be randomly assigned to either a probiotics intervention group or a placebo-controlled group. Both groups will receive prophylactic loperamide according to the FDA-recommended dosing schedule for neratinib-associated diarrhea. Primary Objective: To evaluate the efficacy of probiotics in reducing the incidence and severity of diarrhea in patients receiving Neratinib. Secondary Objectives: This study will also investigate the effects of probiotics on gut microbiota composition and their potential impact on drug efficacy. Study Duration: Enrollment is planned from August 2025 to June 2027 at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. Both the intervention and control groups will receive treatment for a total of six weeks (two cycles of three weeks each). No post-treatment observation period is included. Eligibility Criteria: Participants must be diagnosed with HER2-positive breast cancer and scheduled to receive Neratinib. Exclusion criteria include patients with severe gastrointestinal disorders or recent probiotic consumption.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Probiotics — Participants in this group will receive a daily dose of probiotics as an adjunct to standard Neratinib therapy. The probiotics will be administered orally as a granule formulation dissolved in water, for a total duration of 6 weeks (two treatment cycles). Loperamide will be administered prophylactically according to the FDA-recommended schedule to prevent Neratinib-associated diarrhea. The aim is to assess the efficacy of probiotics in reducing Neratinib-induced diarrhea and improving quality of life.
  • Dietary Supplement: Placebo — Participants in this group will receive a daily dose of a placebo that is identical in appearance, taste, and administration method to the probiotic granules, in addition to standard Neratinib therapy. The placebo will be administered orally as a granule formulation dissolved in water, for a total duration of 6 weeks. Loperamide will also be administered prophylactically to all participants in accordance with FDA recommendations. This group will serve as a control to evaluate the true effect of probiotics on Neratinib-induced diarrhea.
  • Drug: Loperamide — All participants will receive prophylactic loperamide to reduce the risk of Neratinib-induced diarrhea. Loperamide will be administered according to the FDA-recommended schedule: 4 mg TID for the first 14 days of treatment, then 4 mg BID from Day 15 to Day 42. This intervention is implemented as a standard supportive therapy and not as a randomized variable.

Primary Outcomes

  • Incidence of Grade ≥3 Diarrhea (Up to 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-07
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 308 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Jiangnan University
Contact Information
Study Contact:
Jianli Zhao
+86 15920589334
zhaojianli1988@126.com
Jianli Zhao
+86 15920589334
zhaojianli1988@126.com
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Interventions
  • Dietary Supplement: Probiotics — Participants in this group will receive a daily dose of probiotics as an adjunct to standard Neratinib therapy. The probiotics will be administered orally as a granule formulation dissolved in water, for a total duration of 6 weeks (two treatment cycles). Loperamide will be administered prophylactically according to the FDA-recommended schedule to prevent Neratinib-associated diarrhea. The aim is to assess the efficacy of probiotics in reducing Neratinib-induced diarrhea and improving quality of life.
  • Dietary Supplement: Placebo — Participants in this group will receive a daily dose of a placebo that is identical in appearance, taste, and administration method to the probiotic granules, in addition to standard Neratinib therapy. The placebo will be administered orally as a granule formulation dissolved in water, for a total duration of 6 weeks. Loperamide will also be administered prophylactically to all participants in accordance with FDA recommendations. This group will serve as a control to evaluate the true effect of probiotics on Neratinib-induced diarrhea.
  • Drug: Loperamide — All participants will receive prophylactic loperamide to reduce the risk of Neratinib-induced diarrhea. Loperamide will be administered according to the FDA-recommended schedule: 4 mg TID for the first 14 days of treatment, then 4 mg BID from Day 15 to Day 42. This intervention is implemented as a standard supportive therapy and not as a randomized variable.
Study Locations (1 sites)
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong China
Eligibility Criteria
Inclusion Criteria Participants must meet all of the following criteria: 1. Female patients aged ≥18 years, diagnosed with HER2-positive breast cancer. 2. Scheduled to receive Neratinib therapy (monotherapy or in combination), based on clinical guidelines. 3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, with an expected survival of at least 3 months. 4. Left ventricular ejection fraction (LVEF) ≥ 50%. 5. Resolution of any prior treatment-related toxicity to Grade ≤1 (per CTCAE v5.0), with AST and ALT ≤ 2.5 × the upper limit of normal (ULN), and total bilirubin ≤ 1.5 × ULN. 6. Adequate bone marrow function, defined as: White blood cell count ≥ 3.0 × 10⁹/L Neutrophil count ≥ 1.5 × 10⁹/L Platelet count ≥ 100 × 10⁹/L Hemoglobin ≥ 90 g/L Serum creatinine ≤ 1.5 × ULN 7. No persistent gastrointestinal symptoms, such as hematochezia, chronic constipation, or abdominal pain. 8. No evidence of structural gastrointestinal abnormalities confirmed by gastroscopy or other relevant examinations. Exclusion Criteria Participants will be excluded if they meet any of the following criteria: 1. Conditions that significantly impair swallowing, digestion, or gastrointestinal drug absorption. 2. History of chronic gastrointestinal diseases, including but not limited to inflammatory bowel disease (IBD), gastrointestinal tumors, or malabsorption syndromes. 3. Severe cardiovascular diseases that may interfere with study treatment, including but not limited to: Life-threatening arrhythmias Advanced atrioventricular block Unstable angina Clinically significant pericardial disease Myocardial fibrosis Uncontrolled hypertension 4. Known hypersensitivity to any component of Neratinib, probiotics, placebo, or loperamide. 5. Prior participation in any clinical trial involving investigational drugs within 4 weeks prior to enrollment, or chronic use of medications that may induce constipation within 6 months. 6. Pregnant or lactating women, or those unwilling to use effective contraception during the study period. 7. Any medical, psychiatric, or social condition that, in the investigator's judgment, could compromise the safety of the participant, interfere with study participation, or confound the study results.
Conditions Depressive Disorder
Phase PHASE1, PHASE2
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This Phase 2a pilot, exploratory, randomized, double-blind, placebo-controlled, parallel-group trial will estimate whether concurrent fluoxetine alters the antidepressant effect, acute psychedelic experience, or safety of a psychedelic-assisted psychotherapy session in adults with treatment-resistant major depressive disorder (TRD). Eligible participants (ages 25-64) have DSM-5-TR MDD, moderate-severe, MADRS ≥20, and partial response in the current episode (≥1 adequate antidepressant trial of 6-12 weeks with \<50% symptom reduction). All participants receive one dosing session with 3g of standardized Psilocybe mushrooms - with batch assay (e.g., LC-MS) to determine the amount of psilocybin and psilocin present in the sample - with manualized preparation and integration. Participants are randomized 1:1 to fluoxetine 20 mg/day or matching placebo for 4 weeks, started 2 weeks before the psychedelic session and continued 2 weeks after. Masking is quadruple (participant, care provider, investigator, outcomes assessor). The primary outcome is change in MADRS from Baseline to Week 4, assessed by a remote, blinded rater. Key secondary outcomes include response (≥50% MADRS reduction) and remission (MADRS ≤10) at Week 4, and durability at Week 6. Exploratory outcomes assess the psychedelic experience (5D-ASC, SOCQ), psychological flexibility (AAQ-10), and safety/tolerability (UKU and adverse events). Findings will be interpreted as estimates with 95% confidence intervals to inform the design of a subsequent confirmatory trial.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Psilocybin and Psilocyn — Oral dose administered via Psilocybe mushrooms material batch-assayed by LC-MS to standardize psilocybin and psilocyn content.
  • Drug: Placebo — Matching capsules, once daily for 4 weeks (-14 to +14 days).
  • Behavioral: Psychotherapy-assisted session — Same manualized procedures as Arm 1.
  • Drug: Fluoxetine — 20 mg/day for 4 weeks (-14 to +14 days relative to dosing day).

Primary Outcomes

  • Montgomery-Åsberg Depression Rating Scale (MADRS) (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-09-05
Completion: 2026-11-20
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: true
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Federal University of Latin American Integration
Principal Investigators:
  • Francisney P Nascimento, 1 (STUDY_DIRECTOR) - Federal University of Latin American Integration
Contact Information
Study Contact:
Francisney P Nascimento, 1
+55 45 99933-3479
ensaios.clinicos.lcp@unila.edu.br
Francisney P Nascimento, 1
+55 45 99933-3479
ensaios.clinicos.lcp@unila.edu.br
Federal University of Latin American Integration
Interventions
  • Drug: Psilocybin and Psilocyn — Oral dose administered via Psilocybe mushrooms material batch-assayed by LC-MS to standardize psilocybin and psilocyn content.
  • Drug: Placebo — Matching capsules, once daily for 4 weeks (-14 to +14 days).
  • Behavioral: Psychotherapy-assisted session — Same manualized procedures as Arm 1.
  • Drug: Fluoxetine — 20 mg/day for 4 weeks (-14 to +14 days relative to dosing day).
Study Locations (1 sites)
Federal University of Latin American Integration, Foz do Iguaçu, Paraná 85870-650 Brazil
Eligibility Criteria
Inclusion Criteria Age: ≥25 and \<65 years. Diagnosis: Current Major Depressive Disorder (MDD), moderate to severe, per DSM-5-TR, confirmed with SCID-5. Baseline severity: MADRS ≥20 at baseline (reassessed at the pre-dose visit to confirm ongoing eligibility). Partial Response in the current episode (PRD): ≥1 adequate antidepressant trial in this episode (therapeutic dose for ≥6-12 weeks, adherence ≥80%) with \<50% symptom reduction or clinically significant residual symptoms. Clinical stability and ability to provide informed consent; willingness to comply with all study procedures (preparation, dosing session, integration, and follow-ups). Contraception: For participants with reproductive potential, negative pregnancy test and agreement to use effective contraception during the study. Exclusion Criteria Psychiatric disorders: Bipolar I/II disorder, any psychotic disorder, or current MDD with psychotic features; first-degree family history of psychotic or bipolar disorder. Suicide risk: Acute suicidal risk, e.g., active suicidal ideation with intent or plan, recent attempt, or clinical judgment requiring urgent intervention. Interacting medications: Current use of serotonergic antidepressants (SSRI/SNRI/MAOI, clomipramine) or other pro-serotonergic agents (e.g., triptans, linezolid, lithium, tramadol, dextromethorphan) that cannot be discontinued per protocol-defined washout. Other psychotropics: Unstable doses of antipsychotics, mood stabilizers, or long-acting benzodiazepines within the last 2 weeks; need for medications that would compromise blinding on the dosing day. Psychotherapy changes: Initiation or major change in psychotherapy within 2 weeks prior to baseline (to preserve clinical stability). Medical conditions: Clinically significant or unstable medical illness (cardiovascular, neurological, hepatic, renal), prolonged QTc, known hypersensitivity/contraindication to fluoxetine or study materials. Pregnancy or breastfeeding. Substance use: Current substance use disorder (excluding nicotine/caffeine) within the past 3 months; non-medical cannabis use that cannot meet the pre-dose abstinence window (e.g., ≥72 h). Any condition that, in the investigator's opinion, would make participation unsafe or interfere with the assessments. Washout note (to include in Procedures/Eligibility): SSRIs/SNRIs: 7 days or ≥5 half-lives; prior fluoxetine: ≥6 weeks; MAOIs: ≥14 days before randomization/dosing. Participants must be willing and able to follow the washout schedule.
Conditions Hypertension, Cardiovascular Diseases (C...
Phase NA
Enrollment 34
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Royal Jelly — Participants will receive 2 capsules per day, providing the dosage of 300mg of royal jelly for 2 months (8 weeks).
  • Dietary Supplement: Placebo — The placebo group will receive 2 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.

Primary Outcomes

  • Change of inflammatory transcripton factor (Baseline and 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-18
Completion: 2026-12-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 34 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidade Federal Fluminense
Principal Investigators:
  • Ludmila Cardozo, PhD (PRINCIPAL_INVESTIGATOR) - Universidade Federal Fluminense
Contact Information
Study Contact:
Denise mafra, PhD
+5521985683003
dmafra30@gmail.com
Ludmila Cardozo, PhD
+5521987333185
ludmila.cardozo@gmail.com
Denise Mafra
Interventions
  • Dietary Supplement: Royal Jelly — Participants will receive 2 capsules per day, providing the dosage of 300mg of royal jelly for 2 months (8 weeks).
  • Dietary Supplement: Placebo — The placebo group will receive 2 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.
Study Locations (1 sites)
Denise Mafra, Rio de Janeiro, Rio de Janeiro 22260050 Brazil
Eligibility Criteria
Inclusion Criteria: * Diagnosis of stage 1 hypertension * Regular treatment for more than 6 months * No changes in medication doses during the last 3 months Exclusion Criteria: * Autoimmune diseases * Infectious diseases * Diabetes * Chronic kidney disease * Liver disease * Cancer * AIDS * Pregnant women * Use of catabolic drugs or antibiotics * Use of antioxidant vitamin supplements, prebiotics, probiotics, or synbiotics * Habitual intake of royal jelly * Allergy to bee stings * Acute myocardial infarction (AMI) * Stroke (CVA)
Conditions Glaucoma
Phase NA
Enrollment 2000
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if a new screening approach including an artificial intelligence algorithm that analyzes fundus photographs, measurement of eye pressure and visual field testing works to screen for glaucoma. Participants will: Have an image of their fundus (back of the eye) taken as part of their diabetic eye screening Have a measurement of their eye pressure If needed, have a test of their side vision using a headset

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Device: AI-based glaucoma screening — AI analysis of fundus photographs to detect signs of glaucoma, added to AI-based diabetic eye disease screening
  • Device: IOP measurement — Intraocular pressure measurement by Icare tonometer
  • Device: Virtual Reality Visual Field Testing — Virtual Reality Visual Field Testing by the Olleyes device for participants suspected of having glaucoma

Primary Outcomes

  • Glaucoma detection (1 year from initial screening)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-16
Completion: 2030-09
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts Eye and Ear Infirmary
Collaborators: Centers for Disease Control and Prevention
Principal Investigators:
  • David S Friedman, MD, PhD, MPH (PRINCIPAL_INVESTIGATOR) - Massachusetts Eye and Ear
Contact Information
Study Contact:
David S Friedman, MD, PhD, MPH
617-573-3094
grass@mgb.org
David S Friedman, MD, PhD, MPH
617-573-3094
grass@mgb.org
Massachusetts General Hospital Internal Medicine Associates
David S Friedman, MD, PhD, MPH
617-573-3094
grass@mgb.org
Brigham and Women's Primary Care Associates of Longwood
Interventions
  • Device: AI-based glaucoma screening — AI analysis of fundus photographs to detect signs of glaucoma, added to AI-based diabetic eye disease screening
  • Device: IOP measurement — Intraocular pressure measurement by Icare tonometer
  • Device: Virtual Reality Visual Field Testing — Virtual Reality Visual Field Testing by the Olleyes device for participants suspected of having glaucoma
Study Locations (7 sites)
Massachusetts General Hospital Internal Medicine Associates, Boston, Massachusetts 02114 United States
Brigham and Women's Primary Care Associates of Longwood, Boston, Massachusetts 02115 United States
Massachusetts General Hospital Broadway Primary Care-Revere, Boston, Massachusetts 02151 United States
MGH Chelsea HealthCare Center, Chelsea, Massachusetts 02150 United States
NSPG Lynn, Lynn, Massachusetts 01904 United States
NSPG Salem, Salem, Massachusetts 01970 United States
NSPG Saugus, Saugus, Massachusetts 01906 United States
Eligibility Criteria
* Individuals with diabetes undergoing AI-based screening for diabetic retinopathy using the LumineticsCore (Digital Diagnostics) system at primary care centers. * Individuals who are able and willing to provide informed consent for participation in the study.
Conditions Treatment Resistant Hypertension
Phase PHASE2
Enrollment 64
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized, double-blind, placebo-controlled study is to assess whether the food supplement Endocalyx lowers blood pressure in patients with treatment resistant hypertension.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Endocalyx Pro — 4 capsules once daily OR 2 capsules twice daily
  • Other: Placebo — 4 capsules once daily OR 2 capsules twice daily

Primary Outcomes

  • Change from baseline in 24-hour systolic blood pressure (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-21
Completion: 2028-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: Dutch Heart Foundation, Dutch Kidney Foundation, Microvascular Health Solutions LLC
Contact Information
Study Contact:
Rik Olde Engberink, MD PhD
0031205661930
r.h.oldeengberink@amsterdamumc.nl
Sanédy Simon, MD
0031205667789
s.s.a.simon@amsterdamumc.nl
Rik Olde Engberink, MD PhD
+31(0)205661930
r.h.oldeengberink@amsterdamumc.nl
Amsterdam UMC
Interventions
  • Dietary Supplement: Endocalyx Pro — 4 capsules once daily OR 2 capsules twice daily
  • Other: Placebo — 4 capsules once daily OR 2 capsules twice daily
Study Locations (1 sites)
Amsterdam UMC, Amsterdam, North Holland 1105 AZ Netherlands
Eligibility Criteria
Inclusion Criteria: 1. Treatment resistant hypertension defined as 1. an uncontrolled office BP (≥140/90 mmHg). 2. is on a regimen of ≥3 adequately dosed antihypertensive agents of different classes, including a diuretic, at maximum tolerated dose based on investigator judgment. 2. Stable diuretic and antihypertensive treatment for the previous 3 weeks. 3. Subject, or legal representative, has voluntarily signed and dated an Informed Consent Form, approved by the Independent Ethics Committee (IEC). Exclusion Criteria: 1. Age \<18 years. 2. Estimated glomerular filtration rate (eGFR) \<20 ml/min/1.73m2 measured by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula and the 2012 cystatin C CKD-EPI formula. 3. A mean seated systolic blood pressure of at least 180 mmHg or a diastolic blood pressure of at least 110 mmHg. 4. Known secondary hypertension 5. An acute coronary syndrome, stroke, transient ischemic attack or cardiovascular surgery in the last 3 months. 6. Hospitalization for heart failure in the past 3 weeks. 7. Dialysis treatment or expected initiation of dialysis within 3 months of screening. 8. Women of child bearing potential who are not taking adequate contraception (i.e. \<1% failure rate). 9. Planned surgery in the next 12 weeks 10. Major surgery in the previous 4 weeks. 11. Use of prednisolone \>5 mg/day 12. Use of any other investigational drug. 13. Presence of significant comorbidities (e.g., advanced malignancy, advanced liver disease) with a life expectancy of less than 1 year. 14. A psychiatric, addictive or any disorder that compromises ability to give truly informed consent for participation in this study. 15. Known hypersensitivity to seaweed, corn, artichoke, grape, melon or to any of the excipients of Endocalyx. 16. Known hypersensitivity or allergies for milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat and soybeans. 17. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose galactose malabsorption.
Conditions Metastatic Breast Cancer, Recurrent Brea...
Phase PHASE1
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This a phase 1 study to evaluate the safety and preliminary efficacy of cisplatin combined with bortezomib in patients with recurrent or metastatic breast cancer.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Bortezomib (B) — 1.3mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
  • Drug: Cisplatin (CDDP) — 50mg/m2, IV, D1-3, every 3 weeks
  • Drug: Bortezomib (B) — 1.5mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
  • Drug: Bortezomib (B) — 1.7mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
  • Drug: Cisplatin (CDDP) — 70mg/m2, IV, D1-3, every 3 weeks

Primary Outcomes

  • Dose-limiting toxicities (DLTs) (Within 28 days after the first dose.)
  • Maximum Tolerated Dose (MTD) (Within 28 days after the first dose.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-01-01
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-sen University
Principal Investigators:
  • Yan-xia Shi, Doctor (PRINCIPAL_INVESTIGATOR) - Sun Yat-sen University
Contact Information
Study Contact:
Yanxia Shi, Doctor
86-020-87343486
shiyx@sysucc.org.cn
Yanxia Shi, Doctor
86-020-87343486
shiyx@sysucc.org.cn
Sun Yat-Sen University Cancer Center
Yanxia Shi, Doctor
Sun Yat-Sen University Cancer Center
Interventions
  • Drug: Bortezomib (B) — 1.3mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
  • Drug: Cisplatin (CDDP) — 50mg/m2, IV, D1-3, every 3 weeks
  • Drug: Bortezomib (B) — 1.5mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
  • Drug: Bortezomib (B) — 1.7mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
  • Drug: Cisplatin (CDDP) — 70mg/m2, IV, D1-3, every 3 weeks
Study Locations (1 sites)
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510000 China
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18 years and above with pathologically confirmed recurrent or metastatic advanced breast cancer ; 2. The patient has tumor specimens (formalin-fixed, paraffin-embedded or fresh pre-treated recurrent tumor tissue); 3. Patients who have failed standard treatment in the late stage; 4. At least one measurable lesion; 5. ECOG PS : 0-2 points; 6. Estimated survival period ≥12 weeks; 7. The function level of major organs meets the following standards: 1\) The blood routine examination standards must meet: ANC ≥1.5×109/L, PLT ≥75×109/L, Hb ≥85g/L (no blood transfusion and blood products within 14 days, no use of G-CSF and other hematopoietic stimulating factors for correction) 2) Biochemical examinations must meet the following standards: TBIL \<1.5×ULN, ALT, AST \<2.5×ULN, ALT, AST \<5×ULN for patients with liver metastasis, BUN and Cr ≤1×ULN or endogenous creatinine clearance ≥50ml/min (Cockcroft-Gault formula); 8. Women of childbearing age must have taken reliable contraceptive measures, or have undergone a pregnancy test (serum or urine) within 7 days before enrollment, with a negative result, and are willing to use appropriate contraceptive methods during the trial and 8 weeks after the last administration of the trial drug. 9\. The subjects voluntarily join this study, have good compliance, and cooperate with follow-up. Exclusion Criteria: Any of the following will be considered as meeting the exclusion criteria of the study: 1. Patients with acute active hepatitis B or acute active hepatitis C; 2. Any serious underlying disease, comorbidity and active infection 3. Currently receiving other anti-tumor treatments; 4. History of epilepsy or epileptic-induced condition; 5. Patients who are pregnant or breastfeeding; 6. Those with poor compliance or unable to undergo normal follow-up; 7. Allergic to study drugs; 8. Patients diagnosed with other malignant tumors within 5 years, except for the following: surgically resected non-melanoma skin cancer, adequately treated cervical carcinoma in situ, surgically radically treated ductal carcinoma in situ, or malignant tumors diagnosed 2 years ago with no current evidence of disease and untreated ≤ 2 years before randomization; 9. The researcher determines other situations that may affect the conduct of the clinical study and the determination of the study results.
Conditions Depression - Major Depressive Disorder, ...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Amplification of Positivity - Cannabis Use (AMP-C) — AMP-C is a smartphone-based digital intervention that includes activities that focus on positivity (e.g., noticing and capitalizing on positive events) to increase positive emotions, thoughts, and behaviors. The role and impact of CU on the maintenance of depression and reward dysfunction (and vice versa), is intertwined throughout the intervention.

Primary Outcomes

  • Change in Depressive Symptoms (Patient Health Questionnaire-9; PHQ-9) (Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: Intervention Midpoint (4 weeks into intervention), 1-, 3-, 6-, and 12-months after completing intervention)
  • Change in Cannabis Use Frequency (Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory; DFAQ-CU) (Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: Intervention Midpoint (4 weeks into intervention), 1-, 3-, 6-, and 12-months after completing intervention)
  • Usability (System Usability Scale; SUS) (Post-Intervention (approximately one week after completing intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-23
Completion: 2029-06-29
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: National Institute on Drug Abuse (NIDA)
Contact Information
Study Contact:
Shirley Wu, BS
617-724-3532
swu24@mgh.harvard.edu
Massachusetts General Hospital
Amanda C Collins, PhD
Massachusetts General Hospital
Interventions
  • Behavioral: Amplification of Positivity - Cannabis Use (AMP-C) — AMP-C is a smartphone-based digital intervention that includes activities that focus on positivity (e.g., noticing and capitalizing on positive events) to increase positive emotions, thoughts, and behaviors. The role and impact of CU on the maintenance of depression and reward dysfunction (and vice versa), is intertwined throughout the intervention.
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: * Aged ≥ 18 years * Resides in the United States * Able to read and understand English and willing to provide informed consent/comply with the study protocol * Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9) * Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R) * Current elevated anhedonia, as indicated by the PHQ-9 * Interest in receiving treatment for their cannabis use and depression * Meet criteria for current MDD and CUD per the DSM-5 Exclusion Criteria: * History of a psychotic disorder or bipolar disorder type I/II * Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale * Current psychotherapy engagement * Changes in psychotropic medication within six weeks of the start of study
Conditions Essential Hypertension
Phase NA
Enrollment 6
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective and exploratory clinical study, enrolling patients with essential hypertension. This study is planned to be conducted in 2 research institutions in China, and a total of 6 subjects are planned to be included. After the subjects sign the informed consent form (ICF) approved by the ethics committee, they will enter the screening procedure. Subjects who meet the inclusion criteria and do not meet any of the clinical exclusion criteria will be enrolled after undergoing renal artery CTA angiography. All patients will undergo clinical evaluation and blood pressure measurement during the operation, at the time of discharge, and at 1 month, 2 months, 3 months, and 6 months after the operation. It is recommended that the anti-hypertensive medications used before the operation should not be changed within 6 months after the operation for the cases. When the systolic blood pressure (SBP) is ≥ 180 mmHg or there are clinical symptoms caused by hypertension, the drug dosage should be increased as a priority, and then the anti-hypertensive medications should be adjusted. When the systolic blood pressure (SBP) is ≤ 120 mmHg or there are clinical symptoms caused by a decrease in blood pressure, the anti-hypertensive medications should be reduced.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Ultrasonic Nerve Ablation System — Treatment of patients with essential hypertension using the ultrasonic nerve ablation system

Primary Outcomes

  • The change in the average daytime systolic blood pressure two months after the operation (Two months after the operation)
  • Major adverse events within 30 days after the operation (Within 30 days after the operation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-08
Completion: 2026-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 6 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shenzhen Pulsecare Medical Technology Co., Ltd.
Contact Information
Study Contact:
Jingfeng J wang, Postdoctoral fellow
02081332199
wangjingfeng2017@163.com
Wang Jing Feng, professor
0086-020-81332199
the Second Affiliated Hospital of Sun Yat-sen University (Sun Yat-sen Memorial Hospital)
Interventions
  • Procedure: Ultrasonic Nerve Ablation System — Treatment of patients with essential hypertension using the ultrasonic nerve ablation system
Study Locations (1 sites)
the Second Affiliated Hospital of Sun Yat-sen University (Sun Yat-sen Memorial Hospital), Guangzhou, Guangdong 510120 China
Eligibility Criteria
Inclusion Criteria: Males or females aged 18 years old or above and 65 years old or below; Patients with essential hypertension; Patients who have been stably taking 2 or more antihypertensive drugs at conventional doses continuously for at least 4 weeks before enrollment, and whose blood pressure meets the following conditions: (1) The systolic blood pressure measured in the outpatient clinic is ≥150 mmHg and ≤180 mmHg, and the diastolic blood pressure measured in the outpatient clinic is ≥90 mmHg; (2) The systolic blood pressure measured by 24-hour ambulatory blood pressure monitoring (ABPM) is between 135 mmHg and 170 mmHg; The course of hypertension is more than 6 months; The diameter of the renal artery evaluated by renal artery CTA is ≥3 mm and the length is ≥20 mm; The patient or his/her legal representative signs a written informed consent form approved by the ethics committee before screening; Exclusion Criteria: Complicated with type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (defined as plasma Hb1Ac ≥ 10.0%); Estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73 m²; Previous implantation of an implantable cardioverter-defibrillator (ICD) or a pacemaker; History of myocardial infarction, syncope, intracerebral hemorrhage or cerebral infarction within 6 months before signing the informed consent form; Severe valvular heart stenosis; Any factors that may interfere with blood pressure measurement under any circumstances (for example, the patient has severe peripheral vascular disease, abdominal aortic aneurysm, hemorrhagic disorders such as thrombocytopenia, hemophilia, severe anemia); Patients with sleep apnea syndrome; Females who are pregnant or breastfeeding, or those who have a plan to conceive within the next year; Other serious organic diseases with an expected lifespan of less than 12 months; Participation in other clinical trials before screening and not yet completed; Preoperative exclusion criteria based on CTA imaging: a. Visual inspection shows that the diameter stenosis of the renal artery on either side \> 50% or there is a renal artery aneurysm on either side; b. Previous history of renal artery interventional treatment; Other situations that the investigator deems unsuitable for enrollment.